In an 85-year-old patient on hydralazine three times daily, losartan 100 mg daily, and hydrochlorothiazide 12.5 mg daily who remains hypertensive and has bradycardia, what is the appropriate next step in management?

Management of Resistant Hypertension in an 85-Year-Old with Bradycardia

Replace hydralazine with a dihydropyridine calcium channel blocker (such as amlodipine or extended-release nifedipine) to achieve better blood pressure control without worsening bradycardia, while continuing the losartan/HCTZ combination. 1

Rationale for Medication Adjustment

Why Discontinue Hydralazine

The current regimen is problematic for several reasons:

• Hydralazine increases heart rate through reflex tachycardia 2, which paradoxically may be contributing to the bradycardia issue if the patient's autonomic system is attempting to compensate
• Hydralazine TID is suboptimal dosing - evidence shows it should be given at least twice daily, and once-daily dosing leads to inadequate 24-hour control 3
• Hydralazine is not a first-line agent according to 2024 ESC guidelines, which recommend ACE inhibitors, ARBs, dihydropyridine CCBs, and thiazides/thiazide-like diuretics as first-line treatments 1
• Hydralazine can cause profound hypotension when combined with other antihypertensives, particularly in hospitalized or elderly patients 4, 5

The Optimal Replacement Strategy

Add a dihydropyridine calcium channel blocker to create the guideline-recommended three-drug combination:

• The 2024 ESC guidelines explicitly recommend a RAS blocker (losartan) + dihydropyridine CCB + thiazide/thiazide-like diuretic (HCTZ) as the preferred three-drug combination for uncontrolled hypertension 1
• Dihydropyridine CCBs do NOT cause bradycardia - unlike non-dihydropyridine CCBs (diltiazem, verapamil), the dihydropyridines (amlodipine, nifedipine) do not have negative chronotropic effects 1
• This combination is safe and effective even in very elderly patients (≥75 years) 6

Addressing the Bradycardia

Critical consideration: Before adding medications, evaluate for reversible causes of bradycardia 7:

1. Review if any current medications are causing bradycardia - In this case, none of the current agents (hydralazine, losartan, HCTZ) typically cause bradycardia
2. Assess for metabolic causes: hypothyroidism, electrolyte abnormalities, sleep apnea 7
3. Determine if bradycardia is symptomatic - causing dizziness, syncope, fatigue, or hypoperfusion 7

If bradycardia is symptomatic and no reversible cause is found, permanent pacing should be considered per ACC/AHA/HRS guidelines 7. However, do not let bradycardia prevent appropriate hypertension treatment - the dihydropyridine CCB will not worsen the bradycardia.

Specific Dosing Recommendations

Step 1: Transition Strategy

• Discontinue hydralazine
• Start amlodipine 5 mg daily or extended-release nifedipine 30 mg daily
• Continue losartan 100 mg daily and HCTZ 12.5 mg daily

Step 2: Titration

• If blood pressure remains uncontrolled after 2-4 weeks, increase amlodipine to 10 mg daily or nifedipine ER to 60 mg daily
• The losartan/HCTZ combination at current doses (100 mg/12.5 mg) is already at appropriate levels and has demonstrated safety in very elderly patients 6, 8

Step 3: Consider Single-Pill Combination

• Fixed-dose single-pill combinations are recommended by 2024 ESC guidelines to improve adherence 1
• Consider switching to a commercial triple-combination pill if available, or at minimum use a losartan/HCTZ combination pill

Special Considerations for Age 85

The 2024 ESC guidelines specifically address patients ≥85 years 1:

• Continue BP-lowering treatment lifelong if well tolerated, even beyond age 85
• Target systolic BP of 120-129 mmHg if well tolerated, or use the "as low as reasonably achievable" (ALARA) principle if not 1
• Monitor for orthostatic hypotension - check standing blood pressures
• Assess for frailty - moderate-to-severe frailty may warrant more cautious BP targets
• Start with lower doses - the HCTZ 12.5 mg is appropriate; elderly patients may need slower titration 9

Monitoring Parameters

After medication adjustment, monitor:

• Blood pressure - both seated and standing to assess for orthostatic hypotension
• Heart rate - ensure bradycardia is not worsening
• Renal function and potassium - losartan/HCTZ combination can affect both, though studies show stability in very elderly patients 6
• Symptoms - dizziness, syncope, fatigue related to either hypotension or bradycardia

Common Pitfalls to Avoid

1. Do not add a beta-blocker - this would worsen bradycardia and is only recommended when there are compelling indications (post-MI, heart failure, angina) 1
2. Do not use non-dihydropyridine CCBs (diltiazem, verapamil) - these cause bradycardia
3. Do not use hydralazine as a chronic antihypertensive in this setting - it's not guideline-recommended and requires multiple daily dosing
4. Do not withhold appropriate BP treatment due to bradycardia alone - address both issues separately if needed